Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial

Alfred Callahan, Pierre Amarenco, Larry B Goldstein, Henrik Sillesen, Mike Messig, Gregory P Samsa, Irfan Altafullah, Lucy Y Ledbetter, Mary J MacLeod, Russell Scott, Michael Hennerici, Justin A Zivin, K Michael A Welch, SPARCL Investigators

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

To perform a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial, which tested the effect of treatment with atorvastatin in reducing stroke in subjects with a recent stroke or transient ischemic attack, to explore the effects of treatment in subjects with type 2 diabetes mellitus or metabolic syndrome (MetS).
Original languageEnglish
Pages (from-to)1245-1251
Number of pages7
JournalArchives of Neurology
Volume68
Issue number10
DOIs
Publication statusPublished - 2011

    Fingerprint

Keywords

  • Adult
  • Aged
  • Aged, 80 and over
  • Cardiovascular Physiological Processes
  • Cholesterol
  • Confidence Intervals
  • Diabetes Mellitus, Type 2
  • Female
  • Heptanoic Acids
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Ischemic Attack, Transient
  • Lipoproteins, HDL
  • Lipoproteins, LDL
  • Male
  • Metabolic Syndrome X
  • Middle Aged
  • Proportional Hazards Models
  • Pyrroles
  • Retrospective Studies
  • Risk Factors
  • Stroke
  • Triglycerides
  • Young Adult

Cite this